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Abstract 
Photoreceptor degeneration is the hallmark of a group of inherited blinding diseases 
collectively termed Retinitis Pigmentosa (RP); a major cause of blindness in humans. RP is at 
present untreatable and the underlying neurodegenerative mechanisms are largely unknown, 
even though the genetic causes are often established. The activation of calpain-type proteases 
may play an important role in cell death in various neuronal tissues, including the retina. We 
therefore tested the efficacy of two different calpain inhibitors in preventing cell death in the 
rd1 human homologous mouse model for RP.  
Pharmacological inhibition of calpain activity in rd1 organotypic retinal explants had 
ambiguous effects on photoreceptor viability. Calpain inhibitor XI had protective effects 
when applied for short periods of time (16h) but demonstrated substantial levels of toxicity in 
both wild-type and rd1 retina when used over several days. In contrast, the highly specific 
calpain inhibitor calpastatin peptide reduced photoreceptor cell death in vitro after both short 
and prolonged exposure, an effect that was also evident after in vivo application via 
intravitreal injection. These findings highlight the importance of calpain activation for both 
photoreceptor cell death but also survival and propose the use of highly specific calpain 
inhibitors to prevent or delay RP. 
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[Introduction] 
Retinitis Pigmentosa (RP) designates a group of genetic diseases causing photoreceptor 
cell death and blindness in humans. RP usually follows a two-stage process in which first the 
rod-type photoreceptors and then the cone-type photoreceptors degenerate (Kennan et al. 
2005). In the developed world, RP is the prevalent cause of hereditary blindness in the 
working age population (Farrar et al. 2002). Although RP causing mutations have been 
identified in 36 genes to date (Retnet database: www.sph.uth.tmc.edu/retnet, information 
retrieved in May 2010), the mechanisms responsible for photoreceptor cell death are still 
largely unknown and currently no treatment is available (Sancho-Pelluz et al. 2008). 
The rd1 mouse is a human homologous animal model for RP that allows investigations 
into the pathological mechanisms of hereditary photoreceptor cell death (Keeler 1924; Farber 
and Lolley 1974; Paquet-Durand et al. 2009), and is characterized by a loss-of-function 
mutation in the gene encoding for the ß-subunit of rod photoreceptor cGMP 
phosphodiesterase 6 (Pde6b) (Bowes et al. 1990). This causes cGMP to accumulate in rd1 
photoreceptors and eventually triggers cell death, via pathways that are now starting to be 
revealed (Farber and Lolley 1974; Paquet-Durand et al. 2009; Sanges et al. 2006).  
An important mechanistic finding relates to calpain-type proteases, which have been shown 
to be expressed and hyperactive in degenerating rd1 photoreceptors (Paquet-Durand et al. 
2006; Paquet-Durand et al. 2007a). The calpains are a group of calcium (Ca2+) – activated 
proteases with 14 known isoforms (Croall and Ersfeld 2007), that have been implicated in 
neurodegeneration in a number of different tissues (Leist and Jaattela 2001; Blomgren et al. 
2007) including retinal ganglion cells (Araujo et al. 2004; Das et al. 2006; Oka et al. 2006) 
and photoreceptors (Gomez-Vicente et al. 2005; Paquet-Durand et al. 2006; Sanges et al. 
2006). Throughout cellular life certain calpains are regulated by the highly specific, 
endogenous calpain inhibitor, calpastatin (Goll et al. 2003; Hood et al. 2004). The 
dissociation of the calpain-calpastatin complex allows for Ca2+-dependent activation of the 
protease (Suzuki et al. 2004; Hood et al. 2004; Li et al. 2004). Overexpression of calpastatin 
has been associated with an increased resistance to injury and reduced neuronal cell death in 
neurodegenerative disease models (Wingrave et al. 2004; Higuchi et al. 2005). Similarly, in 
rd1 mouse photoreceptors but also in other neurodegenerative diseases such as Alzheimer’s, 
excessive activation of calpains and cell death correlates with a strong down-regulation of 
calpastatin (Paquet-Durand et al. 2006; Rao et al. 2008).  
Together these findings offered two important hypotheses for RP research: 1. that 
uncontrolled calpain activity strongly contributes to photoreceptor cell death and 2. that 
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specific calpain inhibitors may prove useful for neuroprotective retinal therapy. We therefore 
tested different calpain inhibitors in rd1 and wild-type (wt) retinae to further investigate the 
importance of calpain for photoreceptor cell death. Our results show that the low molecular 
weight calpain inhibitor XI (CPI XI) can have both beneficial and detrimental effects on 
photoreceptor viability, depending on whether it is applied by an acute or chronic treatment, 
respectively. On the other hand, the highly specific inhibitor calpastatin peptide (CAST) 
consistently exerted strong neuroprotective effects across different in vitro paradigms. 
Furthermore, CAST reduced rd1 photoreceptor cell death in vivo, suggesting a role for certain 
calpain inhibitors in the development of novel RP therapies. 
 
Experimental Procedures 
Animals 
Animals were housed under standard white cyclic lighting, had free access to food and 
water, and were used irrespective of gender. C3H rd1/rd1 (rd1) and control C3H wild-type 
(wt) mice (Sanyal and Bal 1973; Sanges et al. 2006) were used for in vivo and in vitro 
experiments. All procedures were performed in accordance with the Swedish National Animal 
Care and Ethics Committee (permits # M213/03, # M225/04, # M242/07), with the Italian 
Animal Care Ethics Committee (PROT. No. 6916/07), and with the ARVO statement for the 
use of animals in ophthalmic and visual research. Because of the critical changes at post-natal 
day (PN) 11 (Hauck et al. 2006; Sancho-Pelluz et al. 2008), comparisons between rd1 and wt 
were carried out at this age. 
 
Organotypic retinal explant culture 
For in vitro experiments, PN5 animals were sacrificed by decapitation and retinal explants 
were generated as described previously (Caffe et al. 2001). In the present study, explants were 
allowed to adjust to culture conditions for 2 days in vitro (DIV) before being treated for 
another 4 days for what will be referred to here as chronic treatment, or for the last 16 hours 
of the 6 day total incubation, which is hereafter addressed as acute treatment. The end point 
for the experiments thus corresponds to PN11 in vivo (5+2+4 days or 5+5 days +16 hrs). In 
addition to these two different short-term treatments, a long-term treatment was used in which 
cultures where explanted at PN5, allowed to adjust to in vitro culture for 2 DIV, and then 
treated for another 12 DIV until PN19. Explants were maintained under serum-free conditions 
in R16 nutrient medium (Invitrogen, Paisley, Scotland), and the culture medium with or 
without treatment was changed every two days. 
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Two calpain inhibitors were used: Calpain Inhibitor XI (CPI XI; Z-l-Abu-CONH (CH2)3-
morpholine; sometimes referred to as CX295; Calbiochem, San Diego, CA, USA) and 
calpastatin peptide (CAST; Sigma). Calpain inhibitor XI concentration ranged from 0.5 µM to 
100 µM, whereas 20µM was used for CAST treatment (Movsesyan et al., 2004). Controls for 
CPI XI treated retinae were exposed to equivalent amounts of vehicle (DMSO), whereas 
controls for water soluble CAST received regular R16 medium. Upon completion of each 
experiment, the preparations were fixed in 4% paraformaldehyde (PFA) in PBS for 2 h, 
followed by rinsing with PBS and cryoprotecting with 25% sucrose in PBS. Some 
preparations were left unfixed to enable the calpain activity assay (below). 
 
In vivo experiments 
Because of the rapid progression and early onset of the rd1 degeneration, intravitreal 
injections were performed at PN10, approximately 2 days before eye opening. Animals were 
anesthetized with an intraperitoneal injection of 2 ml/100 g body weight of avertin (1.25% 
(w/v) 2,2,2-tribromoethanol and 2.5% (v/v) 2-methyl-2-butanol; SIGMA, Italy). The eye lid 
was opened carefully, a small incision made below the ora serrata and 1 µl of a solution 
containing 100 µM CAST in phosphate buffered saline (PBS) was injected into the eye. 
Sham-treated animals received only PBS. The capillary was maintained in the eye for 
approximately 3 s to avoid reflux. Since the free intraocular volume of the mouse eye at this 
age is approximately 5 µl, the effective inhibitor concentration was estimated to be at 20 µM. 
Animals were sacrificed between 4h and 16h (approx. PN11) after injection. The eyes were 
enucleated and immediately snap frozen on dry ice without fixation. The whole eyes were 
then embedded in Tissue Tek® (Sakura Finetek, Zoeterwoude, The Netherlands) and 
sectioned (12 µm) in a cryotome (HM560 Microm, Walldorf, Germany). The fresh, unfixed 
sections were then used for enzyme activity assays. A total of 12 animals were used for 
intravitreal injection. 
 
Calpain activity assay  
Tissue sections from unfixed retinae were incubated for 15 min in calpain reaction buffer 
(CRB: 25 mM HEPES, 65 mM KCl, 2 mM MgCl2, 1.5 mM CaCl2, 2 mM DTT, pH 7.2). The 
fluorescent calpain substrate CMAC, t-BOC-Leu-Met (A6520, Invitrogen, Carlsbad, CA, 
USA) was then added to CRB at a final concentration of 2 µM and incubated in the dark for 
2h at 37°C. The sections were washed twice for 10 min each in CRB and then mounted with 
Vectashield (Vector, Burlingame, CA, USA). The activity assay generally labeled the cell 
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membranes, while calpain-activity-positive cells additionally showed a bright labeling of the 
nucleus and perinuclear cytoplasm.  
 
Terminal dUTP nick-end labeling (TUNEL) 
Sections were fixed in 4% PFA, and washed four times in PBS, then incubated for 1h in 
20% goat serum. TUNEL staining was done using an in situ cell death detection kit (Roche, 
Mannheim, Germany) conjugated with TMR red. Controls were performed by omitting the 
terminal deoxynucleotidyl transferase enzyme from the labelling solution (negative control) 
and in pretreating the sections for 30 min with DNAse I (Roche, 3U/ml) in 50 mM Tris-HCl, 
pH 7.5, 1 mg/ml BSA to induce DNA strand breaks (positive control). The negative control 
gave no staining at all, while the positive control resulted in general staining of all nuclei in 
all layers of the retina (Paquet-Durand et al. 2007b). 
 
Staining protocol 
Frozen tissue sections or PFA fixed retinae were stained for general histological light 
microscopic analysis with hematoxylin-eosin (HE) according to standard protocols. 
Immunostaining was performed on fixed tissue sections. These were washed 4 times for 10 
minutes each in PBS containing 0.2% Triton X100 (PTX). Blocking solution containing PTX 
and 5% normal serum from the host animal, from which the secondary antibody was obtained, 
was applied for 1h. Primary mouse anti-rhodopsin antibody (MAB5316, Millipore, Solna, 
Sweden) was diluted (1:800) in PTX containing 2% normal serum and applied overnight at 4° 
C. Sections were then washed 4 times for 10 minutes each in PTX and incubated with 
secondary anti-mouse antibody labelled with Alexafluor 488 fluorescent dye (1:250, 
Invitrogen). After 3 more washing steps in PBS, the sections were mounted with Vectashield 
(Vector) or Glycergel (DAKO, Carpinteria, CA, USA). Controls consisted of sections 
processed in parallel without primary antibody and application of the fluorescence detection 
system. 
 
Microscopy, cell counting and statistics 
Histological work was performed on 12 µm frozen sections. Morphological observations 
and routine light microscopy were performed on a Zeiss Axiophot microscope equipped with 
a Zeiss Axiocam digital camera. Fluorescence excitation was provided by a HBO 100W 
halogen lamp. Images were captured using Zeiss Axiovision 4.2 software; image overlays and 
contrast enhancement were done using Adobe Photoshop CS. 
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Percentages of both calpain activity and TUNEL-positive cells were assessed and 
calculated in a blinded fashion as reported previously (Paquet-Durand et al. 2006; Paquet-
Durand et al. 2009). For each animal at least 3 sections were quantified to yield an average 
value, and at least 3 different animals were analyzed for each time-point and genotype. The 
number of photoreceptor rows remaining after long-term in vitro culture (PN5-19) was 
counted manually on HE stained specimens. At least nine values from different sectioning 
levels in central areas of the retina were taken down and averaged for each explant, and these 
values were then used for further calculations and comparisons. Values are given as mean ± 
standard error of the mean (SEM), except for long-term in vitro treatment where lower n-
values required the use of median instead of mean. In cases where single sample groups were 
compared to a control group, statistical significance was tested using unpaired, two-tailed, 
Students t-test and Microsoft Excel Software. For multiple comparisons, statistical 
significance was tested using GraphPad Prism 4.01 Software (GraphPad Software, La Jolla, 
CA, USA) and employing one-way analysis of variance (ANOVA) followed by Bonferroni´s 
multiple comparison post-test. Significance levels were: p<0.05 (*), p<0.01 (**), p<0.001 
(***). 
 
Results 
Effect of calpain inhibitor XI on photoreceptor viability varies by treatment  
We had previously established that, when included in the assay system, calpain inhibitor 
XI (CPI XI) potently reduced the calpain activity that could be visualized in rd1 
photoreceptors ex vivo (Paquet-Durand et al. 2006). We therefore tested the efficacy of this 
inhibitor to rescue rd1 photoreceptors in an in vitro organotypic retinal explant system. Two 
different treatment paradigms were utilized: chronic and acute, as described in Experimental 
Procedures (PN5 + 2 + 4 days in vitro (DIV) and PN5 + 5 DIV + 16 hrs in vitro, 
respectively). The TUNEL assay for dying cells identified a significant, and concentration 
dependent, difference between the outcomes of the chronic and acute treatments (Fig. 1). As 
CPI XI concentration increased, the chronically-treated retinae showed more TUNEL-positive 
cells, particularly in the ONL, but opposite to this, in acutely-treated retinae, their number 
decreased (Fig. 1 A, E; B, F). Thus, at the highest CPI XI concentration (100 µM), chronic 
treatment resulted in a 195% increase in TUNEL-positivity in the ONL (8.3% ± 0.8 SEM, 
n=4, p<0.001) compared to vehicle treated (DMSO) rd1 retinae (4.3% ± 0.2, n=14), while 
after acute treatment the ONL of retinae exhibited 43% less TUNEL-positive cells (CPI XI 
treated: 2.5% ± 0.4, n=4; control: 4.4% ± 0.3, n=12, p<0.01; Fig. 1I). The discrepancy 
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between the effects of chronic and acute treatment was even more obvious when the 
percentage of TUNEL-positive cells was plotted against CPI XI concentration, and a linear 
regression fitted through the data points (Fig. 1J). 
Wild-type (wt) retinae responded to CPI XI treatment in similar ways (Fig. 1 C, G; D, H). 
A comparatively low number of TUNEL-positive cells were seen in the vehicle treated ONL 
(1.6% ± 0.1, n=8), representing a low level of photoreceptor degeneration caused by the 
culture procedure. However, the levels of cell death were significantly increased by chronic 
CPI XI treatment (4.3% ± 0.4, n=10, p<0.001), while acute treatment led to a numerical 
reduction of TUNEL-positive cells in the ONL (CPI XI treated: 0.9% ± 0.2, n=6; control: 
1.5% ± 0.3, n=4, p=0.08; Fig. 1I). 
 
Calpastatin peptide protects rd1 photoreceptors in vitro 
The results of the chronic CPI XI treatment prompted the need to look for a different, less 
toxic calpain inhibitor. When calpastatin peptide (CAST), at the concentration of 20 µM, 
replaced CPI XI under the identical chronic treatment, the percentage of TUNEL-positive 
cells in the rd1 ONL drastically diminished from 3.9% (± 0.4 SEM, n=6) in untreated 
preparations to 1.8% (± 0.2, n=12, p<0.001) in CAST treated specimens. This was statistically 
equivalent to wt control (1.6% ± 0.1, n=8) and correlated with a statistically significant 
decrease of calpain activity-positive cells in the ONL (Fig. 2). Beyond the ONL, cell death 
labeling in the INL and GCL of CAST-treated rd1 and wt retinae did not identify detrimental 
effects of CAST treatment on cultured tissue.  
As judged by TUNEL analyses, CAST had a neuroprotective effect and CPI XI a 
photoreceptor toxic effect in the chronic treatment, in cultures ending at a time-point 
corresponding to PN11. However, at this time-point the rd1 degeneration had not yet led to an 
obvious decrease in the number of ONL cell rows, and it was thus not possible to conclude 
that such treatments affect the long-term survival of photoreceptors. To study this, we 
prolonged the in vitro treatment to 14 DIV until a time-point corresponding to PN19 
(PN5+2+12). Under these conditions, control wt retinae displayed 9.3 rows of photoreceptors 
in the ONL (± 0.3 SEM, n=3) which was significantly decreased by CPI XI (40 µM) 
treatment to 6.8 (± 0.7, n=3, p<0.05). Vehicle treated degenerating rd1 retinae exhibited 3.3 
(± 0.3, n=9; Fig. 3) rows of photoreceptors at PN19. This was further reduced by CPI XI 
treatment (2.8 ± 0.2, n=6), although this difference did not attain statistical significance. In 
clear opposition to this, CAST (20 µM) treatment significantly increased the number of 
surviving rd1 photoreceptor rows by almost 70% (CAST: 5.5 ± 0.9, n=3, p<0.05).  
Comment [F1]: address in dsicussion?! 
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To obtain a further index on the status of the photoreceptors, the expression of rhodopsin 
was analyzed (Fig.3 G-K). Healthy, wt retinae in vivo show rhodopsin expression restricted to 
the outer segments of rod photoreceptors (Fig.3 G), while rd1 retinae, where outer segments 
do not develop properly, present with a partial mislocalization in the cytoplasm of 
photoreceptors, i.e. staining is here readily seen in the ONL (Fig.3 I) (Bowes et al. 1988; 
Sancho-Pelluz et al. 2010).  
In degenerating rd1 retinae cultured until PN19 the size of rod outer segments and 
rhodopsin immunofluorescence was strongly reduced when compared to wt (Fig 3G, I). In wt 
retinae, CPI XI appeared to increase rhodopsin immunoreactivity in the ONL (Fig 3G, H). In 
rd1 explants after long-term CAST treatment, survival of photoreceptors was increased with 
most ONL cells expressing rhodopsin (Fig 3I, K). In the untreated control situation, however, 
many of the remaining ONL cells were rhodopsin-negative and hence most likely cone 
photoreceptors. Still, we cannot exclude the possibility that among the rhodopsin-negative 
cells, in the control, there might have been occasional rods which had lost rhodopsin 
expression. The use of the rhodopsin staining also illustrated a remarkable photoreceptor 
neurite outgrowth into the INL of the untreated rd1 specimens (20.9 ± 2.4 neurites/mm) when 
compared to wt retinae (5.0 ± 0.6 neurites/mm), which resembled what has been reported 
previously for degenerating human rod photoreceptors (Li et al. 1995). However, such rod 
neurite sprouting was strongly reduced in CPI XI treated rd1 retinae (11.2 ± 3.0 neurites/mm) 
but not affected by CAST treatment (24.3 ± 2.9 neurites/mm), suggesting a potential 
dependency of this process on the activity of only certain types of calpains (Fig. 3I-L).  
Taken together, CAST treatment in both short- and long-term retinal culture demonstrated 
a strong pro-survival effect, suggesting a major contribution of calpastatin targets to mutation 
induced rd1 photoreceptor death. At the same time, chronic application of CPI XI clearly had 
detrimental effects on photoreceptors, while the inner retina appeared to be less, or not at all, 
affected. 
 
Inhibition of calpain reduces calpain activity and cell death in vivo 
To explore the outcome of calpain inhibition in vivo in rd1 mice, CAST was injected into 
the vitreous body of the eye. In the first series of experiments, CAST was injected at PN10 
and the percentage of dying photoreceptors was assessed using the TUNEL assay at different 
time-points post-injection. When compared to untreated specimens (Fig. 4A), at 4h post-
injection there was no significant effect, but at 8h and 16h (Fig. 4B) post-injection a strong 
and significant decrease in the number of TUNEL-positive cells was observed (Fig. 4C). At 
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48h an obvious difference between treated and untreated specimens could no longer be noted, 
presumably due to drug clearance and/or degradation. Since the damage to the early post-natal 
mouse eye caused by intravitreal injections is substantial, repeated injection traumas would 
result in severely increased retinal cell death. The considerable delay in the neuroprotective 
effects of CAST treatment in vivo could be due to the fact that at the time of treatment a 
certain number of cells were already compromised to an extent that did not allow rescue 
anymore.  
Since the beneficial effect of the treatment was most pronounced at 16h post-injection, in a 
second set of experiments the effects of CAST treatment on calpain activity and TUNEL 
assay were assessed using this treatment-analysis interval, which hence ends the test at an age 
roughly corresponding to PN11. When compared to untreated or sham-treated specimens, 
CAST injection in vivo led to a clear decrease in the number of cells positive for either calpain 
activity (rd1 CAST: 1.5% ± 0.3, n=3; rd1 sham: 3.6% ± 0.5, n=4, p<0.01) or for TUNEL (rd1 
CAST: 2.1% ± 0.2, n=3; rd1 sham: 3.2% ± 0.2, n=4, p<0.01). 
The reduction in the percentage of dying, TUNEL-positive cells in the rd1 ONL in vivo 
corresponds to the previous in vitro observations and thus confirms the neuroprotective 
effects of CAST treatment. 
 
Discussion 
Calpains have been widely addressed as key agents in processes of degeneration, 
especially in the central nervous system (Movsesyan et al., 2004; Paquet-Durand et al. 2007a; 
Vosler et al. 2008). The present study supports these notions and exhibits the therapeutic 
potential of calpain inhibition in photoreceptor degeneration. Our work further underlines the 
complexity of the calpain system, since the data also demonstrate that certain calpain isoforms 
or related proteases may be necessary components for photoreceptor survival.  
 
Mechanisms of photoreceptor cell death and activation of calpains 
The mutation in the murine homologue of the PDE6B gene causes excessive accumulation 
of cGMP in the rd1 mouse model for RP (Farber and Lolley 1974; Paquet-Durand et al. 
2009). The cGMP targets include cGMP-dependent protein kinase G (PKG), which is 
activated in rd1 photoreceptors, and cGMP activated cyclic nucleotide gated (CNG) ion 
channels (Pilz and Broderick 2005). While CNG channels may allow for increased Ca2+-
influx from extracellular sources (Frasson et al. 1999), PKG dependent phosphorylation of 
inositol 1,4,5-trisphosphate receptors could lead to Ca2+ release from intracellular stores 
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(Wagner et al. 2003). In either case, elevated cytosolic Ca2+ levels would permit activation of 
calpains. Since PKG is 100-fold more sensitive to cGMP than are CNG channels (Lincoln and 
Cornwell 1993), rising cGMP levels might induce a biphasic increase in cytosolic Ca2+, first 
by PKG-dependent mobilization of Ca2+ from intracellular stores and then by CNG channel 
mediated extracellular Ca2+ influx. Interestingly, a cGMP-PKG-dependent activation of 
calpains was demonstrated in osteoclasts (Yaroslavskiy et al. 2007), and this may happen also 
in rd1 photoreceptors, since the increase in PKG activity in these cells (Paquet-Durand et al. 
2009) is concomitant with calpain activation (Paquet-Durand et al. 2006).  
In addition, we have recently shown that rd1 photoreceptor degeneration involves high 
activity of poly (ADP ribose) polymerase [PARP] (Paquet-Durand et al. 2007b), which may 
have a bearing on Ca2+ homeostasis and cause activation of calpains (Vosler et al. 2009). 
Rising intracellular Ca2+ levels could also explain the observed activation of histone 
deacetylases (HDACs) in rd1 photoreceptors (Qiu and Ghosh 2008; Sancho-Pelluz et al. 
2010). HDAC activation strongly impacts gene transcription (Gallinari et al. 2007), and 
correlates with down-regulation of neuroprotective genes such as CREB and calpastatin 
(Kitagawa 2007) in the degenerating rd1 retina (Paquet-Durand et al. 2006; Azadi et al. 
2006). Together, cGMP-dependent activation of PKG, CNG channels, PARP and HDAC 
might constitute an auto-feedback loop that, once triggered, culminates in excessive activation 
of calpains and eventual cell death.  
 
Calpastatin peptide and calpain inhibitor XI 
The effect of calpain inhibitors on photoreceptor cell death in the rd1 mouse was 
approached using both in vitro and in vivo techniques. For the in vitro studies, an organotypic 
retinal explant culture system (Caffe et al. 2001) was used with both acute and chronic 
treatment schedules, and revealed that the outcome on photoreceptor viability depended on 
both the inhibitor and the treatment paradigm used.  
At PN11, under acute (16 h) application used here, CPI XI promoted photoreceptor 
survival in a concentration dependent manner. However, chronic inhibition (4 d), which was 
six times longer in treatment duration, resulted in the complete opposite effect, causing more 
cells to undergo cell death than in untreated explants, again in a concentration dependent 
fashion. The detrimental effect by CPI XI was further corroborated in long-term, PN19 
cultures of wt retinae. The opposing results from acute and chronic inhibition suggest that, 
apart from being able to induce photoreceptor degeneration, calpain activity may 
Deleted: , since as the inhibitor concentration was increased, cell 
survival also increased
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simultaneously be required for normal functioning of photoreceptors in both rd1 and wt 
retinae.  
In contrast to CPI XI, CAST was found to counteract photoreceptor death in all in vitro and 
in vivo paradigms tested and thus served a neuroprotective role regardless of treatment design. 
The difference between the outcomes from the two inhibitors could originate in the manner of 
inhibition. The dipeptidyl - alpha - ketoimide CPI XI (CX295) inhibits the active site of 
calpains (Donkor 2000) and is hence predicted to act on all known calpain isoforms. In 
addition, it may also weakly inhibit cathepsin B (Blomgren et al. 2001). On the other hand, 
the peptidic calpain inhibitor CAST is based on the sequence of the endogenous calpain 
inhibitor calpastatin (Maki et al. 1989) and has thus a different operation mode, since it 
prevents the autolytic cleavage that leads to calpain activation (Goll et al. 2003). CAST is 
generally regarded to be the most specific inhibitor of calpains, and displays high selectivity 
for calpain isoforms associated with the small calpain subunit (calpain 4, CAPN4), which 
include the two main isoforms calpain 1 and 2 (µ- and m-calpain, respectively) as well as 
calpain 9 (Suzuki et al. 2004). This distinction in selectivity and mechanisms may be at the 
root of our differing results in the sense that the photoreceptors may, for their survival, rely on 
the continuous activity of calpain isoforms that can be inhibited by CPI XI, but not by CAST. 
With prolonged time of inhibition by CPI XI, a pro-survival effect would then be outbalanced 
by the detrimental loss of the activities of some calpains. Alternatively, CPI XI may have 
unwanted side-effects such as inhibition of other proteases like cathepsins or the proteasome, 
which again with time might render photoreceptor survival impossible. While both inhibitors 
may score similarly well in inhibiting calpains in cell-free or other test systems, our results 
from a complex neuronal tissue thus strongly indicate vital differences in the mode and/or 
specificity of their respective activities. Another aspect worth considering is that we 
previously reported a reduction in calpastatin mRNA in the retina of the rd1 mouse (Paquet-
Durand et al. 2006). Since CAST in essence mimics calpastatin, its addition to the rd1 retina 
may be seen as a way of counteracting the calpastatin discrepancy, which again fits with a 
better protective effect than when inhibiting calpains in general. The fact that the CAST effect 
was lost relatively soon after in vivo injection, could be due to metabolism or to increased 
demand after after surgical eye opening during intravitreo injections. Additional in vivo 
studies with improved delivery methods will be needed to further establish neuroprotection 
mediated by calpastatin or structurally related inhibitors. Nevertheless, the results obtained 
with CAST treatment underline the benefits of calpain inhibition during photoreceptor 
degeneration, provided the right conditions are applied.  
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Calpain activity in photoreceptor physiology 
High intracellular Ca2+-concentrations are known to occur in many degenerative processes 
and may lead to an excessive activation of calpains, which in turn may cause cell death 
(Suzuki et al. 2004; Vosler et al. 2008). By comparison, the functions of calpains under 
physiological Ca2+-concentrations are less understood, although reports from a range of 
studies suggest involvement in several and diverse processes (Croall and Ersfeld 2007). An 
extended absence of CPI XI sensitive calpain activities – even if this is only partial, as with 
lower inhibitor concentrations here – could thus lead to a cumulative disruption of calpain-
dependent cellular activities. Since photoreceptors have one of the highest protein turn-over 
rates of any cell type (Young 1976), they may be particularly vulnerable to inhibition of 
proteolysis and improper disposal of surplus proteins. Interestingly, calpains of the types 
Lp82/85, which appear to be insensitive to inhibition by calpastatin (Goll et al. 2003), are 
found to play a role in rodent eye lens maturation (Ma et al. 2000). We have reported the 
presence of Lp82/85 calpain in the mouse retina (Paquet-Durand et al. 2006), and these might 
therefore be amongst the calpains inhibited by CPI XI but not by calpastatin. Furthermore, 
calpains have been implicated in proteolysis of arrestin in photoreceptors (Azarian et al. 
1995) and prolonged deactivation of the phototransduction cascade. CPI XI seemingly 
induced an increase in rhodopsin immunofluorescence in the wt ONL. Although this may 
simply reflect general protein accumulation in photoreceptors, it would also be compatible 
with an involvement of calpains in the hydrolysis and/or trafficking of rhodopsin. 
Dysregulated arrestin breakdown, alone or in combination with effects on rhodopsin, could 
thus promote degeneration of photoreceptors in ways similar to those causing retinal 
degeneration via abnormal rhodopsin/arrestin complexes (Chen et al. 2006; Chuang et al. 
2004). Independent of the exact cause for the observed effects, the non-photoreceptor cells of 
the retina appeared to be much more tolerant to calpain inhibition. 
Neurite sprouting in retinal degeneration has been found also in the human retina (Li et al. 
1995), and may be linked to phenomena associated to degeneration in general, such as the 
presence of activated Müller cells, which are known to produce factors that could act 
stimulatory on various neuronal processes (Bringmann et al. 2006). In addition to such a 
mechanism, the excessive neurite sprouting in rd1 photoreceptors may be boosted by their 
high levels of cGMP (Paquet-Durand et al. 2009), since a role of cGMP-PKG signalling in 
neurite outgrowth has been described (Ditlevsen et al. 2007). Interestingly, the sprouting 
effect was blocked by CPI XI, while it was unaffected after CAST treatment. Apart from the 
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possibility that this result could be secondary to effects on, for instance, calpain sensitive 
Müller glia events, calpains are also known to regulate filopodial motility, neurite outgrowth 
(Robles et al. 2003), cell migration and adhesion (Glading et al. 2004; Franco and 
Huttenlocher 2005), which may all be relevant in this context. Although the mechanisms of 
neurite outgrowth are outside of the scope of this report, the results again demonstrate the 
different properties of the two inhibitors and emphasize the importance of studying them in 
parallel.  
 
Conclusion 
While numerous studies have suggested calpain inhibition as a potential approach to 
prevent neurodegeneration in many different experimental systems, including the retina, our 
study for the first time provides data that calpain inhibition may have not only beneficial but 
also detrimental effects. The results bring about important considerations for the 
implementation of calpain inhibitors as therapeutic agents for RP and highlight the need to 
more precisely define calpain substrates. Nevertheless, the strong protective effect of CAST 
both in vitro and in vivo suggests that restriction of calpain inhibition to specific calpains is a 
feasible approach for the treatment of inherited retinal degeneration. In the future, carefully 
targeted and highly selective calpain inhibitors might further improve this. 
 
Acknowledgements 
We thank H. Abdalle and B. Klefbohm for excellent technical assistance and D. Trifunovic 
and M.-T. Peréz for helpful comments and discussions. This work has been supported by 
grants from the EU (RETNET: MRTN-CT-2003-504003, EVI-GENORET: LSHG-CT-2005-
512036), KMA, Synfrämjandets Forskningsfond, Stiftelsen för synskadade i f.d. Malmöhus 
län, Foundation Fighting Blindness (FFB), Swedish Medical Research Council (VRM), 
Crafoord Foundation, Kerstan Foundation, Petrus and Augusta Hedlunds Foundation, Torsten 
och Ragnar Söderbergs Foundation, and Deutsche Forschungs-gemeinschaft (DFG; 
PA1751/1-1), the Telethon Foundation grant (GGP06096), and the US-Sweden Fulbright 
Program. 
 
 
 15 
References 
Araujo C. L., Sampaio N. M., Hokoc J. N. and Blanco Martinez A. M. (2004) Calpain 
inhibitor 2 prevents axonal degeneration of opossum optic nerve fibers. J. Neurosci. 
Res. 77, 410-419. 
Azadi S., Paquet-Durand F., Medstrand P., van Veen T. and Ekstrom P. A. (2006) Up-
regulation and increased phosphorylation of protein kinase C (PKC) delta, mu and theta 
in the degenerating rd1 mouse retina. Mol. Cell Neurosci. 31, 759-773. 
Azarian S. M., King A. J., Hallett M. A. and Williams D. S. (1995) Selective proteolysis of 
arrestin by calpain. Molecular characteristics and its effect on rhodopsin 
dephosphorylation. J. Biol. Chem. 270, 24375-24384. 
Blomgren K., Leist M. and Groc L. (2007) Pathological apoptosis in the developing brain. 
Apoptosis. 12, 993-1010. 
Blomgren K., Zhu C., Wang X., Karlsson J. O., Leverin A. L., Bahr B. A., Mallard C. and 
Hagberg H. (2001) Synergistic activation of caspase-3 by m-calpain after neonatal 
hypoxia-ischemia: a mechanism of "pathological apoptosis"? J. Biol. Chem. 276, 
10191-10198. 
Bowes C., Li T., Danciger M., Baxter L. C., Applebury M. L. and Farber D. B. (1990) Retinal 
degeneration in the rd mouse is caused by a defect in the beta subunit of rod cGMP-
phosphodiesterase. Nature 347, 677-680. 
Bowes C., van Veen T. and Farber D. B. (1988) Opsin, G-protein and 48-kDa protein in 
normal and rd mouse retinas: developmental expression of mRNAs and proteins and 
light/dark cycling of mRNAs. Exp. Eye Res. 47, 369-390. 
Bringmann A., Pannicke T., Grosche J., Francke M., Wiedemann P., Skatchkov S. N., 
Osborne N. N. and Reichenbach A. (2006) Muller cells in the healthy and diseased 
retina. Prog. Retin. Eye Res. 25, 397-424. 
 16 
Caffe A. R., Ahuja P., Holmqvist B., Azadi S., Forsell J., Holmqvist I., Soderpalm A. K. and 
van Veen T. (2001) Mouse retina explants after long-term culture in serum free 
medium. J. Chem. Neuroanat. 22, 263-273. 
Chen J., Shi G., Concepcion F. A., Xie G., Oprian D. and Chen J. (2006) Stable 
rhodopsin/arrestin complex leads to retinal degeneration in a transgenic mouse model of 
autosomal dominant retinitis pigmentosa. J. Neurosci. 26, 11929-11937. 
Chuang J. Z., Vega C., Jun W. and Sung C. H. (2004) Structural and functional impairment of 
endocytic pathways by retinitis pigmentosa mutant rhodopsin-arrestin complexes. J. 
Clin. Invest 114, 131-140. 
Croall D. E. and Ersfeld K. (2007) The calpains: modular designs and functional diversity. 
Genome Biol. 8, 218. 
Das A., Garner D. P., Del Re A. M., Woodward J. J., Kumar D. M., Agarwal N., Banik N. L. 
and Ray S. K. (2006) Calpeptin provides functional neuroprotection to rat retinal 
ganglion cells following Ca2+ influx. Brain Res. 1084, 146-157. 
Ditlevsen D. K., Kohler L. B., Berezin V. and Bock E. (2007) Cyclic guanosine 
monophosphate signalling pathway plays a role in neural cell adhesion molecule-
mediated neurite outgrowth and survival. J. Neurosci. Res. 85, 703-711. 
Donkor I. O. (2000) A survey of calpain inhibitors. Curr. Med. Chem. 7, 1171-1188. 
Farber D. B. and Lolley R. N. (1974) Cyclic guanosine monophosphate: elevation in 
degenerating photoreceptor cells of the C3H mouse retina. Science. 186, 449-451. 
Farrar G. J., Kenna P. F. and Humphries P. (2002) On the genetics of retinitis pigmentosa and 
on mutation-independent approaches to therapeutic intervention. EMBO J. 21, 857-864. 
Franco S. J. and Huttenlocher A. (2005) Regulating cell migration: calpains make the cut. J. 
Cell Sci. 118, 3829-3838. 
 17 
Frasson M., Sahel J. A., Fabre M., Simonutti M., Dreyfus H. and Picaud S. (1999) Retinitis 
pigmentosa: rod photoreceptor rescue by a calcium-channel blocker in the rd mouse. 
Nat. Med. 5, 1183-1187. 
Gallinari P., Di M. S., Jones P., Pallaoro M. and Steinkuhler C. (2007) HDACs, histone 
deacetylation and gene transcription: from molecular biology to cancer therapeutics. 
Cell Res. 17, 195-211. 
Glading A., Bodnar R. J., Reynolds I. J., Shiraha H., Satish L., Potter D. A., Blair H. C. and 
Wells A. (2004) Epidermal growth factor activates m-calpain (calpain II), at least in 
part, by extracellular signal-regulated kinase-mediated phosphorylation. Mol. Cell Biol. 
24, 2499-2512. 
Goll D. E., Thompson V. F., Li H., Wei W. and Cong J. (2003) The calpain system. Physiol 
Rev. 83, 731-801. 
Gomez-Vicente V., Donovan M. and Cotter T. G. (2005) Multiple death pathways in retina-
derived 661W cells following growth factor deprivation: crosstalk between caspases and 
calpains. Cell Death. Differ. 12, 796-804. 
Hauck S. M., Ekstrom P. A., huja-Jensen P., Suppmann S., Paquet-Durand F., van Veen T. 
and Ueffing M. (2006) Differential modification of phosducin protein in degenerating 
rd1 retina is associated with constitutively active Ca2+/calmodulin kinase II in rod outer 
segments. Mol. Cell Proteomics. 5, 324-336. 
Higuchi M., Tomioka M., Takano J., Shirotani K., Iwata N., Masumoto H., Maki M., Itohara 
S. and Saido T. C. (2005) Distinct mechanistic roles of calpain and caspase activation in 
neurodegeneration as revealed in mice overexpressing their specific inhibitors. J. Biol. 
Chem. 280, 15229-15237. 
Hood J. L., Brooks W. H. and Roszman T. L. (2004) Differential compartmentalization of the 
calpain/calpastatin network with the endoplasmic reticulum and Golgi apparatus. J. 
Biol. Chem. 279, 43126-43135. 
 18 
Keeler C. E. (1924) The Inheritance of a Retinal Abnormality in White Mice. Proc. Natl. 
Acad. Sci. U. S. A. 10, 329-333. 
Kennan A., Aherne A. and Humphries P. (2005) Light in retinitis pigmentosa. Trends Genet. 
21, 103-110. 
Kitagawa K. (2007) CREB and cAMP response element-mediated gene expression in the 
ischemic brain. FEBS J. 274, 3210-3217. 
Leist M. and Jaattela M. (2001) Four deaths and a funeral: from caspases to alternative 
mechanisms. Nat. Rev. Mol. Cell Biol. 2, 589-598. 
Li H., Thompson V. F. and Goll D. E. (2004) Effects of autolysis on properties of mu- and m-
calpain. Biochim. Biophys. Acta. 1691, 91-103. 
Li Z. Y., Kljavin I. J. and Milam A. H. (1995) Rod photoreceptor neurite sprouting in retinitis 
pigmentosa. J. Neurosci. 15, 5429-5438. 
Lincoln T. M. and Cornwell T. L. (1993) Intracellular cyclic GMP receptor proteins. FASEB 
J. 7, 328-338. 
Ma H., Shih M., Hata I., Fukiage C., Azuma M. and Shearer T. R. (2000) Lp85 calpain is an 
enzymatically active rodent-specific isozyme of lens Lp82. Curr. Eye Res. 20, 183-189. 
Maki M., Bagci H., Hamaguchi K., Ueda M., Murachi T. and Hatanaka M. (1989) Inhibition 
of calpain by a synthetic oligopeptide corresponding to an exon of the human 
calpastatin gene. J. Biol. Chem. 264, 18866-18869. 
Movsesyan V.A., Stoica B.A., Yakovlev A.G., Knoblach S.M., Lea P.M ., Cernak I., Vink R. 
and Faden A.I. (2004) Anandamide-induced cell death in primary neuronal cultures: 
role of calpain and caspase pathways. Cell Death Differ. 11, 1121-1132. 
Oka T., Tamada Y., Nakajima E., Shearer T. R. and Azuma M. (2006) Presence of calpain-
induced proteolysis in retinal degeneration and dysfunction in a rat model of acute 
ocular hypertension. J. Neurosci. Res. 83, 1342-1351. 
 19 
Paquet-Durand F., Azadi S., Hauck S. M., Ueffing M., van Veen T. and Ekstrom P. (2006) 
Calpain is activated in degenerating photoreceptors in the rd1 mouse. J. Neurochem. 96, 
802-814. 
Paquet-Durand F., Hauck S. M., van Veen T., Ueffing M. and Ekstrom P. (2009) PKG 
activity causes photoreceptor cell death in two retinitis pigmentosa models. J. 
Neurochem. 108, 796-810. 
Paquet-Durand F., Johnson L. and Ekstrom P. (2007a) Calpain activity in retinal 
degeneration. J. Neurosci. Res. 85, 693-702. 
Paquet-Durand F., Silva J., Talukdar T., Johnson L. E., Azadi S., van Veen T., Ueffing M., 
Hauck S. M. and Ekstrom P. A. (2007b) Excessive activation of poly(ADP-ribose) 
polymerase contributes to inherited photoreceptor degeneration in the retinal 
degeneration mouse 1. J. Neurosci. 27, 10311-10319. 
Pilz R. B. and Broderick K. E. (2005) Role of cyclic GMP in gene regulation. Front Biosci. 
10, 1239-1268. 
Qiu Z. and Ghosh A. (2008) A calcium-dependent switch in a CREST-BRG1 complex 
regulates activity-dependent gene expression. Neuron 60, 775-787. 
Rao M. V., Mohan P. S., Peterhoff C. M., Yang D. S., Schmidt S. D., Stavrides P. H., 
Campbell J., Chen Y., Jiang Y., Paskevich P. A., Cataldo A. M., Haroutunian V. and 
Nixon R. A. (2008) Marked calpastatin (CAST) depletion in Alzheimer's disease 
accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST 
overexpression. J. Neurosci. 28, 12241-12254. 
Robles E., Huttenlocher A. and Gomez T. M. (2003) Filopodial calcium transients regulate 
growth cone motility and guidance through local activation of calpain. Neuron 38, 597-
609. 
Sancho-Pelluz J., Alavi M., Sahaboglu A., Kustermann S., Farinelli P., Azadi S., van Veen T., 
Romero F. J., Paquet-Durand F. and Ekstrom P. (2010) Excessive HDAC activation is 
 20 
critical for neurodegeneration in the rd1 mouse. Cell Death Dis 1: e24; 
doi:10.1038/cddis.2010.4 
Sancho-Pelluz J., Arango-Gonzalez B., Kustermann S., Romero F. J., van Veen T., Zrenner 
E., Ekstrom P. and Paquet-Durand F. (2008) Photoreceptor cell death mechanisms in 
inherited retinal degeneration. Mol. Neurobiol. 38, 253-269. 
Sanges D., Comitato A., Tammaro R. and Marigo V. (2006) Apoptosis in retinal degeneration 
involves cross-talk between apoptosis-inducing factor (AIF) and caspase-12 and is 
blocked by calpain inhibitors. Proc. Natl. Acad. Sci. U. S. A. 103, 17366-17371. 
Sanyal S. and Bal A. K. (1973) Comparative light and electron microscopic study of retinal 
histogenesis in normal and rd mutant mice. Z. Anat. Entwicklungsgesch. 142, 219-238. 
Suzuki K., Hata S., Kawabata Y. and Sorimachi H. (2004) Structure, activation, and biology 
of calpain. Diabetes. 53, S12-S18. 
Vosler P. S., Brennan C. S. and Chen J. (2008) Calpain-mediated signaling mechanisms in 
neuronal injury and neurodegeneration. Mol. Neurobiol. 38, 78-100. 
Vosler P. S., Sun D., Wang S., Gao Y., Kintner D. B., Signore A. P., Cao G. and Chen J. 
(2009) Calcium dysregulation induces apoptosis-inducing factor release: cross-talk 
between PARP-1- and calpain-signaling pathways. Exp. Neurol. 218, 213-220. 
Wagner L. E., Li W. H. and Yule D. I. (2003) Phosphorylation of type-1 inositol 1,4,5-
trisphosphate receptors by cyclic nucleotide-dependent protein kinases: a mutational 
analysis of the functionally important sites in the S2+ and S2- splice variants. J. Biol. 
Chem. 278, 45811-45817. 
Wingrave J. M., Sribnick E. A., Wilford G. G., Matzelle D. D., Mou J. A., Ray S. K., Hogan 
E. L. and Banik N. L. (2004) Higher calpastatin levels correlate with resistance to 
calpain-mediated proteolysis and neuronal apoptosis in juvenile rats after spinal cord 
injury. J. Neurotrauma. 21, 1240-1254. 
 21 
Yaroslavskiy B. B., Sharrow A. C., Wells A., Robinson L. J. and Blair H. C. (2007) Necessity 
of inositol (1,4,5)-trisphosphate receptor 1 and mu-calpain in NO-induced osteoclast 
motility. J. Cell Sci. 120, 2884-2894. 
Young R. W. (1976) Visual cells and the concept of renewal. Invest Ophthalmol. Vis. Sci. 15, 
700-725. 
 
 
 22 
Photoreceptor rescue and toxicity induced by different calpain inhibitors  
 
François Paquet-Durand, Daniela Sanges, Julianne McCall, José Silva,  
Theo van Veen, Valeria Marigo, Per Ekström 
 
 
Figure 1: Acute CPI XI treatment preserves photoreceptors while chronic treatment 
induces cell death. The percentages of TUNEL-positive cells in the ONL of rd1 and wt 
retinae illustrate the drastic differences induced by 96h chronic (A, E; C, G) and 16h acute 
(B, F; D, H) inhibition. The quantification of this effect for different concentrations of CPI XI 
in rd1 and wt retinae (I) showed that as inhibitor concentration increased, chronic treatment 
caused more cell death, whereas photoreceptors were dose-dependently rescued after acute 
treatment. This strong discrepancy was also exemplified by linear regression for rd1 
photoreceptor cell death after acute and chronic treatment (J). Images shown are 
representative for the central area of retinal explant cultures. For each time-point retinae from 
at least four different wt or rd1 animals were analyzed. Error bars represent SEM, scale bar in 
H = 100 µm. 
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Figure 2: Calpastatin peptide reduces calpain activity and photoreceptor cell death in 
vitro: Treatment of cultured retinal explants from PN7 to PN11 with 20 µM CAST resulted in 
a significant decrease in the percentage of TUNEL-positive cells (red bars in I) in the rd1 
ONL (A, C), but not in wt (B, D). Similarly, the number of ONL cells showing high calpain 
activity (blue bars in I) was decreased by CAST (E, G). Wild-type (wt) ONL was not affected 
by the treatment (F, H). The quantification (I) is based on cell counts obtained from at least 
three different wt or rd1 retinae. Error bars represent SEM. Images shown are representative 
for the central area of retinal explant cultures, bright staining sometimes visible in the upper 
part of an image relates to the culture membrane. Scale bar in H = 100 µm. 
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Figure 3: Effects of long-term calpain inhibitor treatment on photoreceptor survival: 
Retinal explants from wild-type (wt) and rd1 were cultured for 14 days in vitro (PN5+2+12) 
and exposed to either CPI XI or CAST. H/E staining revealed a significant decrease in the 
number of surviving photoreceptor rows when wt retina was treated with 40 µM CPI XI (A, 
B), suggesting photoreceptor toxicity (quantification of cell rows given in K). Degenerating 
rd1 retina (C) was not significantly affected by CPI XI (D) but showed a considerable and 
significant increase in photoreceptor survival when treated with CAST (E). In cultured wt 
retina, immunofluorescence showed typical distribution of rhodopsin in rod outer segments 
with ONL cells occasionally showing accumulation of rhodopsin in the cytoplasm (F). A 
magnification of the area surrounded by a white rectangle is shown in (f). CPI XI treated wt 
retina showed a marked increase in rhodopsin immunoreactivity in the ONL (G, g). In 
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cultured rd1 retina, rod outer segments and rhodopsin immunofluorescence were strongly 
decreased, while there was unusual photoreceptor neurite outgrowth into the INL (H, h). The 
latter phenomenon was not observed in CPI XI treated rd1 retina (I, i). CAST treatment did 
not alter the neurite outgrowth phenotype but increased photoreceptor survival, without 
apparent preservation of rod outer segments (J, j). A quantification of the calpain inhibition 
effect on photoreceptor neurite outgrowth is given L. Images shown are representative for the 
central area of retinal explant cultures. For each time-point at least three different wt or rd1 
retinae were analysed. Error bars represent SEM, scale bar in K = 100 µm. 
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Figure 4: CAST treatment reduces calpain activity and cell death in vivo: CAST (20 µM) 
was injected into the vitreous body at PN10. When compared to untreated rd1 retina, CAST 
treatment reduced the number of cells positive for cell death (TUNEL assay; A, B) and 
calpain activity (C, D). The merged image (E, F) illustrates the high degree of colocalization 
between TUNEL (red) and calpain activity (blue) positive cells. The protective effect of 
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CAST treatment was maximal at 16h post-injection (G). At this time-point, CAST decreased 
the number of cells positive for calpain (blue bars) and cell death (red bars) significantly (H). 
For each time-point at least three different rd1 animals were analyzed, error bars represent 
SEM, scale bar in B = 100 µm. 
 
 
  
  
 
